Search results
Showing 1 to 15 of 86 results for peripheral arterial disease
Peripheral arterial disease: diagnosis and management (CG147)
This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
This indicator covers the percentage of patients with peripheral arterial disease with a record in the preceding 15 months that aspirin or an alternative antiplatelet is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM33
Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)
NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease
PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)
NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease
Intravascular lithotripsy for calcified arteries in peripheral arterial disease (IPG780)
Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.
View recommendations for IPG780Show all sections
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Evidence-based recommendations on percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. This involves using a baloon to widen the artery at the site of the blockage.
View recommendations for IPG433Show all sections
Sections for IPG433
Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction in adults. This involves using a device to improve blood flow to the penis.
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
This indicator covers establishing and maintaining a register of patients with peripheral arterial disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM32
beliefs about peripheral arterial disease:- What is the effect of people's attitudes and beliefs about their peripheral arterial...